Re-investing profits from medicines enables companies to develop new medicines for patients Average number of years taken to develop successful medicine ² 4.5 years 5.5 years 7.0 years 8.5 years 11.0 years 12.5 years	Time to	\/ \ \/ \/ \/ \/							The pharmaceutics industry develops 90% of medicines
years taken to develop 4.5 years 5.5 years 7.0 years 8.5 years 11.0 years 12.5 years	om medicines nables companies to evelop new medicines								
	rs taken to develop 🖐		4.5 years	5.5 years	7.0 years	8.5 years	11.0 years	12.5 years	
Average cost to research and develop successful medicine ³ £436 million £533 million £710 million £916 million £1.1 billion £1.15 billion	l develop successful 🔓		£436 million	£ 533 million	£710 million	£916 million	£1.1 billion	£1.15 billion	
Number of medicinal candidates tested to 5,000 - 10,000 candidates 10-20 candidates 5-10 candidates 2-5 candidates 1-2 candidates 1 medicine	mber of medicinal adidates tested to			10-20 candidates	5-10 candidates	2-5 candidates	1-2 candidates	1 medicine	
scientists work then search for a computational first time. Studies medicine's efficacy 1,000 to 5,000 and submitted to it, subject to value and to understand molecule, or models, cells and are conducted with in about 100 to patients to generate the regulatory cost-effectiveness about 20 to 100 500 patients with data about safety, agencies assessments and local	medicine ⁴	Based on their disease focus, companies' scientists work to understand the disease	Researchers select a 'target', such as a gene or protein, then search for a molecule, or compound, that may act on the 'target' to alter the disease	testing Early safety and efficacy tests are undertaken in computational models, cells and in animals	clinical trial The candidate medicine is tested in people for the first time. Studies are conducted with about 20 to 100 healthy volunteers	clinical trial Researchers evaluate the candidate medicine's efficacy in about 100 to 500 patients with the disease	clinical trial Researchers study the candidate medicine in about 1,000 to 5,000 patients to generate data about safety, efficacy and the overall benefit-risk relationship of	Information and results from all the studies is compiled and submitted to the regulatory	for patients The medicine is now licensed for use and patients may benefit from it, subject to value and

⁽in 2010 prices based on Bank of England exchange rate)

3 Paul S et al How to improve R&D productivity: the pharmaceutical industry's grand challenge, Nature Reviews Drug Discovery, Volume 9 March 2010

4 PhRMA analysis, updated for data per Tufts Center for the Study of Drug Development (CSDD) database (1995)